Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

  1. Citrome, L.
  2. Sánchez del Rio, M.
  3. Dong, Y.
  4. Nichols, R.M.
  5. Tockhorn-Heidenreich, A.
  6. Foster, S.A.
  7. Stauffer, V.L.
Aldizkaria:
Advances in Therapy

ISSN: 1865-8652,  0741-238X

Argitalpen urtea: 2021

Alea: 38

Zenbakia: 8

Orrialdeak: 4442-4460

Mota: Artikulua

DOI: 10.1007/S12325-021-01848-X GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus